Dabrafenib (GSK2118436)

Catalog No.S2807

Dabrafenib (GSK2118436) Chemical Structure

Molecular Weight(MW): 519.56

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM in cell-free assays, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.

Size Price Stock Quantity  
In DMSO USD 180 In stock
USD 90 In stock
USD 130 In stock
USD 170 In stock
USD 270 In stock
USD 400 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • A375P cells were treated with vehicle, the BRAF inhibitor GSK2118436, the MEK inhibitor GSK1120212, 10 uM HCQ, or the indicated combinations. Shown are 48-hour immunoblots directed against the indicated proteins.

    J Clin Invest 2014 24(3), 1406-17. Dabrafenib (GSK2118436) purchased from Selleck.

    Levels of pERK and tERK in the CLL cells derived from PBMC were measured by Western blot. We used vemurafenib, dabrafenib, and trametinib (0.07 uM) as indicated. One of 3 independent experiments with similar results is shown. CLL cells exposed to dabrafenib or vemurafenib had an elevated pERK/tERK ratio as compared with vehicle (P < 0.01).

    J Clin Invest 2014 124(11), 5074-84. Dabrafenib (GSK2118436) purchased from Selleck.

  • The effects of inhibitors of mutant BRAFV600 inhibitor dabrafenib on cancer cell growth were evaluated by the MTT assay. Cell growth inhibition of FRO and SW1736 cell lines induced by dabrafenib.

    Transl Res 2014 10.1016/j.trsl.2014.06.005. Dabrafenib (GSK2118436) purchased from Selleck.

    Dabrafenib alleviates acetaminophen-induced hepatotoxicity in mice. Mice were treated with 300 mg/kg acetaminophen (i.p.), with or without pretreatment with 300 mg/kg or 100 mg/kg dabrafenib (p.o.).TUNEL staining for nuclear DNA fragmentation in mouse liver cells.

    Cell Death Dis 2014 5, e1278. Dabrafenib (GSK2118436) purchased from Selleck.

  • Western blot analysis of p-Erk and total ERK in A375 melanoma cell line after treatment with different doses of Dabrafenib for 48 hours (A). p-ERK signal was normalized with total ERK signal (B), SD and means of the normalized p-ERK values were reported.

    PLoS One, 2016, 11(3):e0152104. Dabrafenib (GSK2118436) purchased from Selleck.

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM in cell-free assays, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.
Targets
B-Raf (V600E) [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
C-Raf [1]
(Cell-free assay)
0.8 nM 3.2 nM 5.0 nM
In vitro

Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-RafV600E kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-RafV600E. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MVnLbY5ie2ViQYPzZZk> Mn\3TY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFjpd{B1[WepZXSgRk1T[WZiVk[wNGUhdXW2YX70JIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDpcpNm[3RiY3XscJMh[29vZYjwdoV{e2mwZzDDSGM{PyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBjcW:2aX75cIF1\WRvTVXLJJBzd3SnaX6gdIhwe3Cqb4L5cIF1cW:wIHL5JGFteGijU3Py[YVvKGG|c3H5JJdqfGhiSVO1NEBw\iByLkCwNFch|ryP Mnj3NlQ6ODB4N{O=
SK-MEL-28 MUfLbY5ie2ViQYPzZZk> Mlv2NUBp MVLJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfCCrbjDoeY1idiCVSz3NSWwuOjhiY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gSXJMKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFQh|ryP NVXyb4NqOjR7MEC2O|M>
HepG2 Mli3T4lv[XOnIFHzd4F6 MkDITY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRiaX6gbJVu[W5iSHXwS|Ih[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iRWLLJJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMESg{txO NXyxOYhoOjR7MEC2O|M>
COLO205 NHHlbFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M373bWlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OT{KwOUBk\WyuIIDyc4xq\mW{YYTpc44hf2m2aDDJR|UxKG:oIECuNFA4KM7:TR?= MVuyOFkxODZ5Mx?=
HepG2 MYTGeY5kfGmxbjDBd5NigQ>? NUXXSoJLPDVibXnu MVvEUXNQ NHrWTG9KdmirYnn0bY9vKG:oIFHsb|UhcW5iVFfGMYJmfGFvc4TpcZVt[XSnZDDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCVbXHkNkBxcG:|cHjvdplt[XSrb36geJJm[XSnZDDmc5IhPDVibXnud{BxemmxcjD0c{BVT0ZvYnX0ZUB{fGmvdXzheIlwdiCvZXHzeZJm\CCjZoTldkA3OCCvaX7zJIJ6KG:meYPz[Zkh[myxdDDzZ4FvdmW{IHHuZYx6e2m|IIfpeIghUUN3MDDv[kA{NjdizszN M4Kx[lI1QTByNkez
HFF NYjP[WNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWD0cmIzOTBizszN M3zwclczKGh? MUjEUXNQ MkHnTY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;uJI9nKGi3bXHuJGhHTiClZXzsd{Bp[XKkb4Lpcochf2muZDD0fZBmKEJvUnHmJJdqfGhiSVO1NEBw\iB|IN88US=> Mm\3NlM5PDRyM{i=
SK-MEL-28 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;3OWVGOTBizszN M2XJVFczKGh? NV61OXNRTE2VTx?= MXXJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfC2mcnn2[Y4hW0tvTVXMMVI5KGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4xPDNizszN NEjaXGwzOzh2NECzPC=>
A375P-F11 NUXSO29WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX6xNEDPxE1? NHjk[pQ4OiCq M4\4XWROW09? MYfJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfC2mcnn2[Y4hSTN5NWCtSlEyKGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4xPzFizszN M3jlelI{QDR2MEO4
MALME-3M Mo\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfiemoyOCEQvF2= M2nnPFczKGh? MoLVSG1UVw>? NFfGe49KSzVyPUGgcm0> MnPaNlM5PDRyM{i=
UACC-62 NIP3N|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zLWFExKM7:TR?= MUi3NkBp MoHVSG1UVw>? MUHJR|UxRTFibl2= Mmr0NlM5PDRyM{i=
C32TG MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXnNVAh|ryP Mo[0O|IhcA>? MUnEUXNQ MYLJR|UxRTFibl2= NE\5SlAzOzh2NECzPC=>
SK-MEL-1 MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIi2NHUyOCEQvF2= MonVO|IhcA>? MUjEUXNQ NIPpeIpKSzVyPUKgcm0> NI\F[3AzOzh2NECzPC=>
M14 MlzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33Uc|ExKM7:TR?= NUXlbno1PzJiaB?= NHfSOFFFVVOR NUmwXFhEUUN3ME2yJI5O M2S2dFI{QDR2MEO4
SK-MEL-28 NYDKfWJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLXSYMyOCEQvF2= Mlf0O|IhcA>? NIL5PWNFVVOR NH31[5pKSzVyPUOgcm0> M2\CXFI{QDR2MEO4
A375 NVv6cJl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTNNVAh|ryP NIXke5U4OiCq MkTNSG1UVw>? NFfYZmJKSzVyPUSgcm0> M{nsVVI{QDR2MEO4
DU-4475 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\LS3IyOCEQvF2= NFLjZmo4OiCq NVf0b4xqTE2VTx?= NHjGZ5hKSzVyPUWgcm0> MU[yN|g1PDB|OB?=
UACC-257 NITvVXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LSS|ExKM7:TR?= MX:3NkBp MV;EUXNQ NIXDT2xKSzVyPU[gcm0> M{DST|I{QDR2MEO4
Colo 205 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYqxNEDPxE1? MlS0O|IhcA>? MknzSG1UVw>? NV7nW4FmUUN3ME23JI5O NHTBWoUzOzh2NECzPC=>
SK-MEL-3 M4nDS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;1fXBwOTBizszN MWm3NkBp MUnEUXNQ MlvnTWM2OD15IH7N NEjxdoczOzh2NECzPC=>
SH-4 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TYVFExKM7:TR?= NUnw[ZhNPzJiaB?= M4PHRmROW09? Ml:4TWM2OD16IH7N M3\YclI{QDR2MEO4
A101D MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHvcm5iOTBizszN MWm3NkBp NG\xdFNFVVOR MojtTWM2OD17IH7N M4OxOFI{QDR2MEO4
ES-2 NVjXWmkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnVNVAh|ryP M4r2VlczKGh? MXLEUXNQ NV;p[IRiUUN3ME21N{BvVQ>? NW[2NW9pOjN6NESwN|g>
HT-29 NXTJNI9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHCcYtxOTBizszN M3r1dlczKGh? M4nRNWROW09? Mn:wTWM2OD14NjDuUS=> MUWyN|g1PDB|OB?=
SW1417 M3zKbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYSxNEDPxE1? MoLCO|IhcA>? NVm0ZYQ3TE2VTx?= MmO3TWM2OD1zNUigcm0> NXTib|lsOjN6NESwN|g>
SW872 NF7qUG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXixNEDPxE1? M3nX[lczKGh? MnzvSG1UVw>? NIqxOHdKSzVyPUO3O{BvVQ>? NWPxRYxnOjN6NESwN|g>
RKO NInnT5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFr2OYQyOCEQvF2= NXzhO|dJPzJiaB?= MYjEUXNQ NInPfpBKSzVyPUKuOVIzKM7:TR?= M4HlO|I{QDR2MEO4
A673 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjBW4gyOCEQvF2= NYTkSlk3PzJiaB?= M2\UZmROW09? MX3JR|UxRTFyIN88US=> MnTCNlM5PDRyM{i=
GCT MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWWxNEDPxE1? MX[3NkBp M1TmN2ROW09? NGnxd4hKSzVyPUGwJO69VQ>? MVGyN|g1PDB|OB?=
WM-115 NEDQWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEG3VIYyOCEQvF2= MlPiO|IhcA>? MVvEUXNQ MoLLTWM2OD13IH7N MVOyN|g1PDB|OB?=
YUMAC MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXKxNEDPxE1? NUHaWGFnPzJiaB?= MnPHSG1UVw>? MV3JR|UxRTVibl2= M2XFZ|I{QDR2MEO4
OV-90 NFXm[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2m4S|ExKM7:TR?= Mn3WO|IhcA>? M4nsOWROW09? Mo\jTWM2OD1{OTDuUS=> MWqyN|g1PDB|OB?=
NCI-H508 M1PlTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvVNVAh|ryP MYm3NkBp M3LLSWROW09? NVXtVZVRUUN3ME2xNEDPxE1? MmLlNlM5PDRyM{i=
MDA-MB-231 M1;vfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV6xNEDPxE1? MnLJO|IhcA>? NV3KTHhSTE2VTx?= NEG5NJdKSzVyPUGwJO69VQ>? NEW3d2MzOzh2NECzPC=>
SW756 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVn2WI9NOTBizszN M3;TcVczKGh? MYfEUXNQ NHXHV25KSzVyPUGwJO69VQ>? MVuyN|g1PDB|OB?=
SW-837 NGnQW5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj0cY1tOTBizszN MkDSO|IhcA>? MmHjSG1UVw>? MnXuTWM2OD1zMDFOwG0> MVGyN|g1PDB|OB?=
UMUC-3 MmLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nXVVExKM7:TR?= NIDs[mg4OiCq NU\RcIozTE2VTx?= NGnuXZdKSzVyPUGwJO69VQ>? MWOyN|g1PDB|OB?=
LS-174T MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXe1XZB[OTBizszN NYDPXY14PzJiaB?= NEW1fIZFVVOR MnXhTWM2OD1zMDFOwG0> NX3GPYhTOjN6NESwN|g>
A549 M4TqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVSyNVV3OTBizszN MnXSO|IhcA>? NFq5Z5pFVVOR NV\RenhbUUN3ME2xNEDPxE1? NXzxdYpZOjN6NESwN|g>
SHP-77 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\PNVAh|ryP Mm\TO|IhcA>? MnvYSG1UVw>? NHTBbXRKSzVyPUGwJO69VQ>? NVKxSpNVOjN6NESwN|g>
SW480 NUTYWG9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[yOFExKM7:TR?= Mnr4O|IhcA>? MX\EUXNQ NGPx[YlKSzVyPUGwJO69VQ>? MWeyN|g1PDB|OB?=
DLD-1 M2TyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjvd|RMOTBizszN MWK3NkBp MV\EUXNQ NIfWNXJKSzVyPUGwJO69VQ>? M1fZSlI{QDR2MEO4
HCT-116 NH\sZo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7LNVAh|ryP MX63NkBp MnT2SG1UVw>? NVT3O3g5UUN3ME2xNEDPxE1? NGS2UWMzOzh2NECzPC=>
NCI-H747 NGfnOnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLie5JCOTBizszN MYi3NkBp MWDEUXNQ M3TFZ2lEPTB;MUCg{txO M{n3OFI{QDR2MEO4
T-84 MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf4O2EyOCEQvF2= NXPrPXJiPzJiaB?= Mn60SG1UVw>? M2PGbGlEPTB;MUCg{txO NXzCW5ZzOjN6NESwN|g>
NCI-H460 NWnnVGpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TBNlExKM7:TR?= MmDKO|IhcA>? NUPVT5N[TE2VTx?= NITtdY5KSzVyPUGwJO69VQ>? M4r0RlI{QDR2MEO4
Calu-6 NHvROm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moj0NVAh|ryP MXS3NkBp MXHEUXNQ MnSzTWM2OD1zMDFOwG0> NXnLe|Y6OjN6NESwN|g>
HCC-2998 MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXvNVAh|ryP NWfKSpRLPzJiaB?= M13xeGROW09? M{jEd2lEPTB;MUCg{txO NYrOPWZMOjN6NESwN|g>
LS1034 NWfadppvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[0V|ExKM7:TR?= M{TiVFczKGh? MkPxSG1UVw>? NX;XUXB6UUN3ME2xNEDPxE1? M3W3OFI{QDR2MEO4
CHP-212 NXr6R2pnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXqxNEDPxE1? NIfwNYc4OiCq NIjvW2tFVVOR NVr5W4NHUUN3ME2xNEDPxE1? NFXhNW8zOzh2NECzPC=>
SK-N-AS MmXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\YNVAh|ryP MmPXO|IhcA>? MmDxSG1UVw>? MXTJR|UxRTFyIN88US=> MWeyN|g1PDB|OB?=
BFTC-905 MoG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnFdWxCOTBizszN MXq3NkBp NIXPUHhFVVOR MkfCTWM2OD1zMDFOwG0> MYqyN|g1PDB|OB?=
HuT78 NYHnVphNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYOxNEDPxE1? NH;NSmo4OiCq M4foW2ROW09? NHrRW2NKSzVyPUWyJI5O NGPRfYYzOzh2NECzPC=>
RPMI-8226 M3TwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zFZlExKM7:TR?= M1v4U|czKGh? NHWy[49FVVOR M4jRfmlEPTB;Mk[zJI5O NYr1fIt5OjN6NESwN|g>
BC-3 M{fO[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfaO|A2OTBizszN NGPXWoE4OiCq NWLwbnVbTE2VTx?= M1jBVGlEPTB;Mke3JI5O M1jTOFI{QDR2MEO4
ACHN M4q1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXKzb21wOTBizszN MXK3NkBp NVLs[2pzTE2VTx?= NYXp[mtPUUN3ME2yPVQhdk1? MlXqNlM5PDRyM{i=
JRT3-T35 NGTBW2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfJencyOCEQvF2= MmrmO|IhcA>? MWnEUXNQ NYD4d3h5UUN3ME2yPVUhdk1? M1vjPFI{QDR2MEO4
SK-MES-1 NU\OWG9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVSxNEDPxE1? NHzqOG84OiCq NVnN[Y8xTE2VTx?= M1W4NGlEPTB;M{K5JI5O M{nIR|I{QDR2MEO4
CESS MnfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYGxNEDPxE1? MXK3NkBp MYnEUXNQ NX3WVFNnUUN3ME20PVchdk1? M4TXelI{QDR2MEO4
H4 NV2wPFBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHEcJp3OTBizszN NV3Xd3JpPzJiaB?= NYDBRnB1TE2VTx?= MXzJR|UxRTZzOTDuUS=> MnTuNlM5PDRyM{i=
BC-1 NGH1[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3xNVAh|ryP NIjyUpE4OiCq NU\E[4xUTE2VTx?= M{\IcWlEPTB;N{C0JI5O NIn0SFczOzh2NECzPC=>
DB NVrjPVdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTLe3AyOCEQvF2= NGO5doM4OiCq NUXDdmNYTE2VTx?= MUXJR|UxRTh5MzDuUS=> MoHkNlM5PDRyM{i=
RPMI-6666 NVzzZWN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoX0NVAh|ryP M3;SV|czKGh? M4fsWWROW09? MVfJR|UxRTl{ODDuUS=> NVzLNok{OjN6NESwN|g>
MC/CAR MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWixNEDPxE1? MUS3NkBp NIi1cnhFVVOR MmjFTWM2OD1zLkCwNkDPxE1? MlXwNlM5PDRyM{i=
SNU-1 M4CxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVyxNEDPxE1? NUnwSHFCPzJiaB?= M4PobmROW09? MWTJR|UxRTFwNUCxJO69VQ>? NXvX[ZhOOjN6NESwN|g>
CEM/C1 MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVK2NoY1OTBizszN MV:3NkBp MW\EUXNQ MXHJR|UxRTFwN{ezJO69VQ>? NUX3dnlJOjN6NESwN|g>
GDM-1 M1H3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HibFExKM7:TR?= Mnm1O|IhcA>? M3zncWROW09? MYjJR|UxRTFwOUm3JO69VQ>? NIjVS2wzOzh2NECzPC=>
HT-1080 NYGydXp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVK0OoNXOTBizszN NGXFdlI4OiCq NVHmV3BvTE2VTx?= NH3JXGdKSzVyPUKuNFA1KM7:TR?= M2nUeFI{QDR2MEO4
HL-60 M3r1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLxNVAh|ryP NGrPb5U4OiCq M1TmfGROW09? Ml3zTWM2OD1{LkG3PEDPxE1? Mn3KNlM5PDRyM{i=
C3A Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUOxNEDPxE1? Ml3sO|IhcA>? NF3zPYJFVVOR NH:3OohKSzVyPUWuOFE1KM7:TR?= MVGyN|g1PDB|OB?=
MES-SA NIXG[|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nTSFExKM7:TR?= M330[lczKGh? NV\NNZhrTE2VTx?= NXy1Ook6UUN3ME22Mlk5QSEQvF2= NFj3RpYzOzh2NECzPC=>
22Rv1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWixNEDPxE1? M3z1TVczKGh? M333OGROW09? MoLQTWM2OD1zMDFOwG0> MlPQNlM5PDRyM{i=
647-V NHPKT4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnCNVAh|ryP MoW1O|IhcA>? M2HnXmROW09? MlPyTWM2OD1zMDFOwG0> M1viO|I{QDR2MEO4
786-O MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojvNVAh|ryP MkfqO|IhcA>? NX\BWo9ETE2VTx?= MorNTWM2OD1zMDFOwG0> MUmyN|g1PDB|OB?=
A172 NH\1OJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW[xNEDPxE1? MWq3NkBp NH7SVZJFVVOR M1S1d2lEPTB;MUCg{txO MXSyN|g1PDB|OB?=
A204 NInI[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\SNVAh|ryP MXW3NkBp MWHEUXNQ MUDJR|UxRTFyIN88US=> MWCyN|g1PDB|OB?=
A427 NHTGSmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLR[2MyOCEQvF2= NIrGOng4OiCq MlrLSG1UVw>? MWDJR|UxRTFyIN88US=> NFTZWVAzOzh2NECzPC=>
A431 NEL5bZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjjN|QyOCEQvF2= MlHNO|IhcA>? NYL1WVVzTE2VTx?= MVHJR|UxRTFyIN88US=> NEWzUIszOzh2NECzPC=>
A2780 MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknKNVAh|ryP NUHqb5ZmPzJiaB?= NVnleZVtTE2VTx?= MX;JR|UxRTFyIN88US=> NEH6N4QzOzh2NECzPC=>
ARH-77 M3;Icmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrDdpRtOTBizszN MWW3NkBp NWWyeppwTE2VTx?= M2rqc2lEPTB;MUCg{txO MofjNlM5PDRyM{i=
Be(2)C M2foRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfzNVAh|ryP NWjFcVRIPzJiaB?= MXrEUXNQ M4K4UWlEPTB;MUCg{txO M2fNNFI{QDR2MEO4
BT-20 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;k[JR4OTBizszN MmroO|IhcA>? MULEUXNQ NYHhT5p3UUN3ME2xNEDPxE1? NI\BZXIzOzh2NECzPC=>
BxPc3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3P5clExKM7:TR?= NXjOfFgzPzJiaB?= NXzjco85TE2VTx?= MVTJR|UxRTFyIN88US=> M3\IcFI{QDR2MEO4
C-4 I Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXOb3FqOTBizszN MlLDO|IhcA>? NYKwd2V[TE2VTx?= M1HWcmlEPTB;MUCg{txO M2\ZPFI{QDR2MEO4
C33A M4\q[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknMNVAh|ryP MkPSO|IhcA>? MlP5SG1UVw>? MWjJR|UxRTFyIN88US=> Mmf5NlM5PDRyM{i=
CAL-27 M{PmWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nMNVExKM7:TR?= NH;sbZg4OiCq MUTEUXNQ MUjJR|UxRTFyIN88US=> MkLmNlM5PDRyM{i=
CAL-62 NXfa[Fc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7FNVAh|ryP NHq1TW84OiCq M4fwWmROW09? MWTJR|UxRTFyIN88US=> M3W2N|I{QDR2MEO4
Calu-3 M2XwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\qNVEyOCEQvF2= MlfBO|IhcA>? MkLqSG1UVw>? M2HUZ2lEPTB;MUCg{txO MWqyN|g1PDB|OB?=
CaOV3 MlHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTiNVAh|ryP NXHXSm1mPzJiaB?= NITjV3ZFVVOR M{HYfWlEPTB;MUCg{txO MoHBNlM5PDRyM{i=
CGTHW1 M3TRb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUGzNlJNOTBizszN NGm1S2o4OiCq MXjEUXNQ MUfJR|UxRTFyIN88US=> NX\nU|I4OjN6NESwN|g>
CHL-1 M{nrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jyWlExKM7:TR?= MWi3NkBp MWjEUXNQ NX\lVIszUUN3ME2xNEDPxE1? NEjxTlIzOzh2NECzPC=>
Colo320DM NVfhTW5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXKxNEDPxE1? NH;Y[HU4OiCq NH3odIlFVVOR NFq2VHFKSzVyPUGwJO69VQ>? M{LsTlI{QDR2MEO4
Colo704 NV\rTGNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV6xNEDPxE1? NU\iTm17PzJiaB?= NUnoNok3TE2VTx?= NYLr[mw1UUN3ME2xNEDPxE1? MViyN|g1PDB|OB?=
COR-L23 MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf2XZIyOCEQvF2= NFnDXJg4OiCq Mlf2SG1UVw>? NUPKToNtUUN3ME2xNEDPxE1? Mnz2NlM5PDRyM{i=
CRO-AP2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LRVlExKM7:TR?= NIXSdJI4OiCq NVPjWZBqTE2VTx?= MX7JR|UxRTFyIN88US=> MXuyN|g1PDB|OB?=
Daudi NVrxSI9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXGVWl5OTBizszN MoKxO|IhcA>? MoOzSG1UVw>? NGf4b2NKSzVyPUGwJO69VQ>? M{fBU|I{QDR2MEO4
DOTC 24510 NGj4b4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTMVZEyOCEQvF2= NUjHe5JvPzJiaB?= NGC0PHhFVVOR NVTvOnE6UUN3ME2xNEDPxE1? NWrSbXlxOjN6NESwN|g>
DU-145 MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLRNVAh|ryP NHq1OlY4OiCq NEnYS2pFVVOR Mmi0TWM2OD1zMDFOwG0> NWPEdmVYOjN6NESwN|g>
EB-3 NFzKfoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLDc4YyOCEQvF2= MojGO|IhcA>? MUnEUXNQ NIq5eVdKSzVyPUGwJO69VQ>? NIPmWYwzOzh2NECzPC=>
EFM-19 M4nsSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXTZmExOTBizszN MXW3NkBp Mli0SG1UVw>? MUfJR|UxRTFyIN88US=> NH7vOIozOzh2NECzPC=>
EKVX NFvZNZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7pWI4yOCEQvF2= NGe5UGE4OiCq MUPEUXNQ MkDVTWM2OD1zMDFOwG0> M1rNeFI{QDR2MEO4
FaDu NEnV[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH5VHZ{OTBizszN M4nBU|czKGh? NEHGRmhFVVOR NYPGVXc3UUN3ME2xNEDPxE1? NULJ[4Q6OjN6NESwN|g>
G401 NEeyW3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV2xNEDPxE1? MYq3NkBp MWLEUXNQ MXfJR|UxRTFyIN88US=> M1:xWFI{QDR2MEO4
HCC-70 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zpSlExKM7:TR?= MX:3NkBp MmLkSG1UVw>? MknmTWM2OD1zMDFOwG0> MWeyN|g1PDB|OB?=
HCC-1954 M{HSb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3OxUlExKM7:TR?= NVfoZVFLPzJiaB?= M4LqbWROW09? M1rmcGlEPTB;MUCg{txO M{mwbVI{QDR2MEO4
Hela Mn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\ONVAh|ryP NV3iO49bPzJiaB?= MkftSG1UVw>? NXT2Nm05UUN3ME2xNEDPxE1? NGjnbGkzOzh2NECzPC=>
Hep3B M2nCeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrSdlRMOTBizszN MWq3NkBp MoHQSG1UVw>? Mk\vTWM2OD1zMDFOwG0> NEDxZ20zOzh2NECzPC=>
HMCB MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofNNVAh|ryP MWK3NkBp M3\S[GROW09? MluwTWM2OD1zMDFOwG0> NEHp[HUzOzh2NECzPC=>
HN5 NXHqR4JGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTl[m01OTBizszN M4\qTVczKGh? MUTEUXNQ NUXubJNWUUN3ME2xNEDPxE1? M{XXc|I{QDR2MEO4
HOS Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3WzO|ExKM7:TR?= NGnT[Zo4OiCq NXXwXFdFTE2VTx?= MYrJR|UxRTFyIN88US=> NXWxRWJmOjN6NESwN|g>
HPAF-II NYnLSIdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXyxNEDPxE1? MUG3NkBp M3Tye2ROW09? NXTsXZhKUUN3ME2xNEDPxE1? MXGyN|g1PDB|OB?=
Hs746.T MkDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVSxNEDPxE1? NVvyZ3psPzJiaB?= NGn0d|NFVVOR NVTtNJFUUUN3ME2xNEDPxE1? MkfvNlM5PDRyM{i=
HT NITjZ|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4WxblExKM7:TR?= M3yy[VczKGh? NEjLUmRFVVOR M2TvSGlEPTB;MUCg{txO NXTwdohvOjN6NESwN|g>
HT-3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnCNHBxOTBizszN M2\heFczKGh? M3vGUWROW09? MVLJR|UxRTFyIN88US=> MnvjNlM5PDRyM{i=
HuNS-1 NFXScHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nzUFExKM7:TR?= NU\icmRxPzJiaB?= MWXEUXNQ NXn1W2ZCUUN3ME2xNEDPxE1? NX7EOodtOjN6NESwN|g>
IGROV1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonMNVAh|ryP MlHIO|IhcA>? MULEUXNQ MYHJR|UxRTFyIN88US=> NIHhT3MzOzh2NECzPC=>
J82 NHPKNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjlSXpUOTBizszN MojOO|IhcA>? M4G1eWROW09? M{Lu[mlEPTB;MUCg{txO NEXjZnczOzh2NECzPC=>
JM1 NV7JTFNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXVfGpHOTBizszN M2jMRlczKGh? NH3BRmZFVVOR NEX6OG5KSzVyPUGwJO69VQ>? MX[yN|g1PDB|OB?=
Kato III MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXaOldFOTBizszN NEG5W2E4OiCq MnPISG1UVw>? MWLJR|UxRTFyIN88US=> NWr4SW5WOjN6NESwN|g>
KHOS-240S M1nXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\JNVAh|ryP M3PNVlczKGh? NW\wfmprTE2VTx?= MUnJR|UxRTFyIN88US=> M4G2S|I{QDR2MEO4
KM-12 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4m5XFExKM7:TR?= NGfnbZk4OiCq NG[4R|JFVVOR M2rEUGlEPTB;MUCg{txO M1j3c|I{QDR2MEO4
KPL-1 NFL5[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWK1[5dZOTBizszN MYi3NkBp NHj4TnRFVVOR M3ewZWlEPTB;MUCg{txO MWSyN|g1PDB|OB?=
KYSE-30 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DOb|ExKM7:TR?= NH3QTmo4OiCq NF\nZZlFVVOR NXS0SZZsUUN3ME2xNEDPxE1? MYOyN|g1PDB|OB?=
LNCaP NX\uUIMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkH4NVAh|ryP MWW3NkBp NGO0ZYtFVVOR NEG4cFFKSzVyPUGwJO69VQ>? NHLB[IEzOzh2NECzPC=>
MCF-7 MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX2xNEDPxE1? Mkf6O|IhcA>? MYLEUXNQ NUW3cJVQUUN3ME2xNEDPxE1? M3PKXlI{QDR2MEO4
MC-IXC Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrzfWh3OTBizszN NUnEfllTPzJiaB?= M1L1NmROW09? Mn3qTWM2OD1zMDFOwG0> M4LOPFI{QDR2MEO4
MDA-MB-175 VII M2fKV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TpcVExKM7:TR?= MoTyO|IhcA>? MWHEUXNQ MXHJR|UxRTFyIN88US=> M4\kRlI{QDR2MEO4
MDA-MB-468 MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHH5fJgyOCEQvF2= NXH3WI17PzJiaB?= NWHT[3A3TE2VTx?= MoraTWM2OD1zMDFOwG0> MnfkNlM5PDRyM{i=
MiaPaCa NVixTHdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVyxNEDPxE1? MVq3NkBp NXW4Z3V2TE2VTx?= M1TJNmlEPTB;MUCg{txO NYm2bow2OjN6NESwN|g>
Molt-4 NHL5WoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYCxNEDPxE1? NVzTSohpPzJiaB?= MVTEUXNQ M4PC[2lEPTB;MUCg{txO NULkbZlIOjN6NESwN|g>
NCI-ADR/RES M2nrNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mme1NVAh|ryP NIHRO3Q4OiCq MV\EUXNQ MVjJR|UxRTFyIN88US=> MUGyN|g1PDB|OB?=
NCI-H69 M2DrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUKxNEDPxE1? M{\STFczKGh? MmTzSG1UVw>? NUPjcmtMUUN3ME2xNEDPxE1? NF3JXJczOzh2NECzPC=>
NCI-H82 NH75R3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TxOlExKM7:TR?= NVLUS2FSPzJiaB?= M1rUc2ROW09? M1HObGlEPTB;MUCg{txO Mo[xNlM5PDRyM{i=
NCI-N87 NFexcVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjyNVAh|ryP M2PPSFczKGh? MYPEUXNQ MkDBTWM2OD1zMDFOwG0> MmjENlM5PDRyM{i=
NCI-H146 MnP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWGxNEDPxE1? MWe3NkBp MVfEUXNQ MUPJR|UxRTFyIN88US=> MVGyN|g1PDB|OB?=
NCI-H157 NYjDcGs1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nFe|ExKM7:TR?= MnO0O|IhcA>? NInrcpBFVVOR MnjLTWM2OD1zMDFOwG0> M3r2[|I{QDR2MEO4
NCI-H187 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TafVExKM7:TR?= M1rJe|czKGh? NUXwZ4EzTE2VTx?= NFyz[29KSzVyPUGwJO69VQ>? MWiyN|g1PDB|OB?=
NCI-H209 MlzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnxNVAh|ryP M2ToOVczKGh? Mn\HSG1UVw>? MVrJR|UxRTFyIN88US=> MUOyN|g1PDB|OB?=
NCI-H226 NFqwfGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PPPVExKM7:TR?= NIX2VYs4OiCq NIfDeHlFVVOR MojCTWM2OD1zMDFOwG0> MWOyN|g1PDB|OB?=
NCI-H292 NEXkfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFu3VmgyOCEQvF2= NXHvdo0zPzJiaB?= MVjEUXNQ NHjn[mdKSzVyPUGwJO69VQ>? MkfxNlM5PDRyM{i=
NCI-H322 M3HoVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[xNEDPxE1? NGrvXY04OiCq M2KzbGROW09? NFXsNW1KSzVyPUGwJO69VQ>? M{DCclI{QDR2MEO4
NCI-H358 NHnHU2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEK0XFQyOCEQvF2= MWW3NkBp MXPEUXNQ NUjIV4ZWUUN3ME2xNEDPxE1? MUCyN|g1PDB|OB?=
NCI-H520 NYXyTXJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVyxNEDPxE1? NV7kZWFEPzJiaB?= M4LyVGROW09? NXPEZWxiUUN3ME2xNEDPxE1? MYmyN|g1PDB|OB?=
NCI-H526 NW\M[ZF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r5dlExKM7:TR?= M3LlZ|czKGh? NUmyOYhCTE2VTx?= M{DZ[mlEPTB;MUCg{txO M1LBSVI{QDR2MEO4
NCI-H630 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPoNVAh|ryP M2ezNlczKGh? MlzoSG1UVw>? MWrJR|UxRTFyIN88US=> M{fGbVI{QDR2MEO4
NCI-H661 NWPRe|V{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWKxNEDPxE1? Mnm2O|IhcA>? NF[5fINFVVOR MWXJR|UxRTFyIN88US=> NHnEOWEzOzh2NECzPC=>
NCI-H716 NIHZ[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1f2TlExKM7:TR?= NFXqTmk4OiCq NEfyVY1FVVOR MX\JR|UxRTFyIN88US=> NXPOV2pGOjN6NESwN|g>
NCI-H1563 Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIKyZXcyOCEQvF2= M1TDdVczKGh? NHz6PJZFVVOR MVvJR|UxRTFyIN88US=> NY[yUpoxOjN6NESwN|g>
NCI-H1792 NGrBcZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPteWhrOTBizszN MnL4O|IhcA>? NEfycJZFVVOR M1jDOWlEPTB;MUCg{txO MnfjNlM5PDRyM{i=
NCI-H2030 Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXOxNEDPxE1? MVK3NkBp MY\EUXNQ NFv5XItKSzVyPUGwJO69VQ>? M3XtclI{QDR2MEO4
NCI-H2052 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPKUm9kOTBizszN M2HqUFczKGh? MmfUSG1UVw>? M{TwS2lEPTB;MUCg{txO M4\TZlI{QDR2MEO4
NCI-H2122 MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETBXlYyOCEQvF2= NGDQOJc4OiCq M{PJZmROW09? M{HWdGlEPTB;MUCg{txO MV6yN|g1PDB|OB?=
NCI-H2228 NYLvSZZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zPe|ExKM7:TR?= MX23NkBp NIS1PGhFVVOR M4m5OWlEPTB;MUCg{txO MYKyN|g1PDB|OB?=
OE-19 M2jDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjDbVMyOCEQvF2= M1nUTlczKGh? MXvEUXNQ NIfkNI1KSzVyPUGwJO69VQ>? NWrFZZgyOjN6NESwN|g>
OE-21 MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3vTWgyOCEQvF2= M{\lR|czKGh? M1PMcmROW09? NW\ORW9rUUN3ME2xNEDPxE1? NF3XdFAzOzh2NECzPC=>
OE-33 NX7DSol3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUWxNEDPxE1? M2Xj[|czKGh? NUO4XW1MTE2VTx?= MnHETWM2OD1zMDFOwG0> M3u3OVI{QDR2MEO4
OVCAR-3 NXv0RmJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[wNVAh|ryP MWS3NkBp Ml;YSG1UVw>? MmW4TWM2OD1zMDFOwG0> MYOyN|g1PDB|OB?=
OVCAR-4 M{L0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrwZmFSOTBizszN NXvOdJJUPzJiaB?= MlfwSG1UVw>? NYHmOnB7UUN3ME2xNEDPxE1? NYDoXpFDOjN6NESwN|g>
OVCAR-5 NEe5TYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEf1dXMyOCEQvF2= M2O3bVczKGh? M{HacmROW09? M2HJOGlEPTB;MUCg{txO NYH4e3NEOjN6NESwN|g>
P3HR-1 NVLqOlZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzHe2gyOCEQvF2= MXm3NkBp M{DKbmROW09? NHnobGZKSzVyPUGwJO69VQ>? MX2yN|g1PDB|OB?=
PC-3 M1PDc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTyNVAh|ryP NXu2VnFOPzJiaB?= NX\2S41NTE2VTx?= MV3JR|UxRTFyIN88US=> MWOyN|g1PDB|OB?=
Raji Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmH4NVAh|ryP MlvVO|IhcA>? MoC5SG1UVw>? MmruTWM2OD1zMDFOwG0> M3r5blI{QDR2MEO4
RD NUjZPGVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf2VVZ2OTBizszN NVezVVkyPzJiaB?= MXrEUXNQ NGD5[GRKSzVyPUGwJO69VQ>? M{O2OlI{QDR2MEO4
RD-ES M3O5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:wS3cyOCEQvF2= NHm1SnQ4OiCq NUjEbVc5TE2VTx?= MVzJR|UxRTFyIN88US=> NEfS[JkzOzh2NECzPC=>
RL NV3mTIpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2L5R|ExKM7:TR?= M{LjUVczKGh? NEnNWlZFVVOR NHXxPXJKSzVyPUGwJO69VQ>? NEe5XHUzOzh2NECzPC=>
SaOS2 M2WzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TITFExKM7:TR?= M4W1VFczKGh? MU\EUXNQ M{PWdWlEPTB;MUCg{txO NWHoc5FCOjN6NESwN|g>
SCC-9 M2Ppfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TFc|ExKM7:TR?= M2DQblczKGh? MoD0SG1UVw>? M2LGdGlEPTB;MUCg{txO NXKxUnQ3OjN6NESwN|g>
SCC-12 NEHmUFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\iS49bOTBizszN NVHPO2JEPzJiaB?= NYK0XIZkTE2VTx?= NHvvcpFKSzVyPUGwJO69VQ>? NVjKb4tpOjN6NESwN|g>
SCC-13 NXSwO2F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXkSm1ROTBizszN M3TydVczKGh? MoXSSG1UVw>? M1;6RWlEPTB;MUCg{txO NYrQTYdTOjN6NESwN|g>
SCC-15 NEfNZ5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYSxNEDPxE1? NIj2XG84OiCq NYnNe|cxTE2VTx?= NXniTVV5UUN3ME2xNEDPxE1? NXnBUFc5OjN6NESwN|g>
SCC-25 MlTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXmxNEDPxE1? NE\tRlE4OiCq MU\EUXNQ Mn64TWM2OD1zMDFOwG0> NYO0WGd7OjN6NESwN|g>
SCLC-3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XiVFExKM7:TR?= MUC3NkBp M2fZbWROW09? NEjQSHBKSzVyPUGwJO69VQ>? NVL5VmhvOjN6NESwN|g>
SF-268 NFnD[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fIO|ExKM7:TR?= MX63NkBp NX\BdVV3TE2VTx?= M3r0bWlEPTB;MUCg{txO NUTxW3E5OjN6NESwN|g>
SF-295 NIDFW|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\hSFExKM7:TR?= MVm3NkBp NXf1SpcxTE2VTx?= NFj2UZNKSzVyPUGwJO69VQ>? M1\jZVI{QDR2MEO4
SJRH30 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXOxNEDPxE1? NVLBeWhXPzJiaB?= M2TqcWROW09? M2DzTmlEPTB;MUCg{txO NI\3b3QzOzh2NECzPC=>
SK-BR-3 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPENVAh|ryP M2S2UFczKGh? M{\SfmROW09? MV3JR|UxRTFyIN88US=> NUPncWVbOjN6NESwN|g>
SK-LMS-1 M17HV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PKWVExKM7:TR?= NGLOXoM4OiCq NHPLZWNFVVOR M4WzVmlEPTB;MUCg{txO MV6yN|g1PDB|OB?=
SK-N-DZ M1zTW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTCWoMyOCEQvF2= M{jBXVczKGh? M3f1bGROW09? MkXPTWM2OD1zMDFOwG0> MnKzNlM5PDRyM{i=
SK-N-F1 NXLmZpNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVX3[|ZHOTBizszN MlHoO|IhcA>? MUjEUXNQ NELFNoxKSzVyPUGwJO69VQ>? MWeyN|g1PDB|OB?=
SKOV-3 M1vUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUCySJN3OTBizszN NWXiRWw{PzJiaB?= NXj2c3dpTE2VTx?= MnLRTWM2OD1zMDFOwG0> M3nGN|I{QDR2MEO4
SK-UT-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUCxNEDPxE1? MXe3NkBp MWLEUXNQ NFLCfJVKSzVyPUGwJO69VQ>? MoLnNlM5PDRyM{i=
SN12C NIDHNHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nDWFExKM7:TR?= NGDxd4Y4OiCq NWLu[|h7TE2VTx?= NF\NdIhKSzVyPUGwJO69VQ>? MYWyN|g1PDB|OB?=
SNB-19 NWi4cWpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4WxUFExKM7:TR?= NYLNd3NiPzJiaB?= M2[4XmROW09? NYfCXIdUUUN3ME2xNEDPxE1? NVuxd4VWOjN6NESwN|g>
SNU-5 M3:zcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYKxNEDPxE1? MXi3NkBp MmrrSG1UVw>? NU[4VVJZUUN3ME2xNEDPxE1? NHXTfmczOzh2NECzPC=>
SNU-16 MnfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4iwXlExKM7:TR?= MXW3NkBp NITTOYdFVVOR M1n5WmlEPTB;MUCg{txO NXiy[ml[OjN6NESwN|g>
SNU-398 M3zEdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSxNEDPxE1? NWf3XlQxPzJiaB?= MmXQSG1UVw>? NEGwSZlKSzVyPUGwJO69VQ>? NXjLZnJKOjN6NESwN|g>
SNU-449 M3\QdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XsTlExKM7:TR?= MXy3NkBp MkD3SG1UVw>? Mlr0TWM2OD1zMDFOwG0> MXKyN|g1PDB|OB?=
SR NVXPRmpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDUcIF1OTBizszN M3vZ[lczKGh? MYLEUXNQ NHfjWYlKSzVyPUGwJO69VQ>? MXKyN|g1PDB|OB?=
ST486 NUjhXmtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3jUoUyOCEQvF2= M2nzOVczKGh? NFnyfIlFVVOR NWrFUZQ3UUN3ME2xNEDPxE1? NWHsVnpuOjN6NESwN|g>
SW579 NIPXdVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzNNVAh|ryP M3XTOVczKGh? NIPSbHJFVVOR NHW2XWFKSzVyPUGwJO69VQ>? Mnj6NlM5PDRyM{i=
SW684 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUWwXo1jOTBizszN NH;O[nc4OiCq MX\EUXNQ NVvEclZ3UUN3ME2xNEDPxE1? MXiyN|g1PDB|OB?=
SW-780 NEK0eJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnDPWFwOTBizszN M1vNTlczKGh? NVPoSFZsTE2VTx?= NYW5OmE2UUN3ME2xNEDPxE1? NYTvPIVWOjN6NESwN|g>
SW900 NW[yUHFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFj0fpUyOCEQvF2= NEfyfGk4OiCq NG\F[nRFVVOR NET6XZZKSzVyPUGwJO69VQ>? MUKyN|g1PDB|OB?=
SW1088 NF\WOJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnDT4NvOTBizszN NYDUbVhxPzJiaB?= NHz2Vm1FVVOR MmD1TWM2OD1zMDFOwG0> MUiyN|g1PDB|OB?=
SW1463 NGDJN2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXDW3YyOCEQvF2= M1XvOVczKGh? M4\JbGROW09? MkHoTWM2OD1zMDFOwG0> M2jnO|I{QDR2MEO4
SW1990 NHvYcWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\kd5UyOCEQvF2= NXG0TYg{PzJiaB?= NXHiTGsxTE2VTx?= MUXJR|UxRTFyIN88US=> MlfUNlM5PDRyM{i=
T47D MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUixNEDPxE1? Mn23O|IhcA>? NYrKUlBMTE2VTx?= NFmzOlNKSzVyPUGwJO69VQ>? M2HhS|I{QDR2MEO4
TE381.T MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPyXpkyOCEQvF2= Moq4O|IhcA>? M1zvSmROW09? NEWyU4NKSzVyPUGwJO69VQ>? MV6yN|g1PDB|OB?=
TK-10 MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf6RZgyOCEQvF2= M4HKe|czKGh? M3TNemROW09? Mn22TWM2OD1zMDFOwG0> MUmyN|g1PDB|OB?=
U2OS NFzk[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\Ne5AyOCEQvF2= NXzw[oloPzJiaB?= MYjEUXNQ NHrzVJlKSzVyPUGwJO69VQ>? NVKyb2Z4OjN6NESwN|g>
U251 MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVexNEDPxE1? M4DrOFczKGh? NEH5V2JFVVOR NF3DXXNKSzVyPUGwJO69VQ>? M{nIflI{QDR2MEO4
UACC-812 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPScZJVOTBizszN M3\MWlczKGh? NEXqUW9FVVOR M1LPNmlEPTB;MUCg{txO M4Pa[FI{QDR2MEO4
YAPC NHvofVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XQflExKM7:TR?= NUixOYFPPzJiaB?= MkfnSG1UVw>? M2qxd2lEPTB;MUCg{txO MYSyN|g1PDB|OB?=
ZR-75-1 NILTcmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUKxNEDPxE1? MlzrO|IhcA>? NXzpboZ2TE2VTx?= NVXMbXZ6UUN3ME2xNEDPxE1? M{DO[lI{QDR2MEO4
A375 NYDKXmc4TnWwY4Tpc44h[XO|YYm= MV:xMlIh|ryP NIjFRXI1KGh? M3TCNmROW09? M1niNGlvcGmkaYTpc44hd2ZicHjvd5Bpd3K7bHH0bY9vKG:oIF3FT{whTVKNLDDhcoQhWz[S NYXVTJIyOjJ|OEm0O|E>
YUSIT1 M1n2eWZ2dmO2aX;uJIF{e2G7 NXPaXotMTE2VTx?= Mn\pdoVlfWOnZDDz[Y5{cXSrdnn0fUB4cXSqIFnDOVAhRiByLkWg{txO M2jyZVIzOzh7NEex
MeWo NFTvZY9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1u2cWROW09? NWPMN4JKUUN3MDC9JFk5PyCwTR?= NIn6fZEzPjBzOEWyOC=>
WiDr M1jDUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUe0TmtuTE2VTx?= M4LiNWlEPTBiPTC3OkBvVQ>? M4r3dlI3ODF6NUK0
Colo-205 MVXGeY5kfGmxbjDhd5NigQ>? MUOxJO69VQ>? M37WRVQh\A>? NEThU5hFVVOR NVy2eYFyUW6mdXPl[EBiKGirZ3jsfUBkd22yYYLhZoxmKGOxbYDhZ5Rqd25icHjlco91gXCn Mn;jNlU{QDFzNUK=
RBW-1 M2TMdmZ2dmO2aX;uJIF{e2G7 MWqxJO69VQ>? NFHOc2FFVVOR MV3Oc{Bz\WS3Y4Tpc44hd2ZiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44> M1zjTlI1QDh3Nkmw
RBO-1 MmnKSpVv[3Srb36gZZN{[Xl? NUC2[VVYOSEQvF2= MVPEUXNQ NH\DUlNKdmirYnn0bY9vKG:oIF3lb{AyNzJicHjvd5Bpd3K7bHH0bY9v MlPYNlQ5QDV4OUC=
RBO-2 NYrjZoJlTnWwY4Tpc44h[XO|YYm= MVWxJO69VQ>? NXXROnNNTE2VTx?= NWK5SlhIUW6qaXLpeIlwdiCxZjCgUYVsKDFxMjDwbI9{eGixconsZZRqd25? NWjKXJF7OjR6OEW2PVA>
RBOW M1HJVmZ2dmO2aX;uJIF{e2G7 Ml\qNUDPxE1? NYTRRYdYTE2VTx?= Mnz0TY5pcWKrdHnvckBw\iBiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44> NFW4NGQzPDh6NU[5NC=>
M257 NGnRRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPyfXcyODBibl2= NX3MWHZSPzJiaB?= NFTmR4JFd2W|IH7veEBqdmirYnn0JJBzd2yrZnXyZZRqd25ib3[gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[= NH\vcHIzOzNzN{S0Oi=>
LCP Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\MN5MzOTByIH7N MYm3NkBp MmC0TY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;uJI9nKEyFUDDj[YxtKGijcnLveZJqdmdiQmLBSkBXPjByUjDteZRidnSjdHnvci=> NHnNblkzOzNzN{S0Oi=>
WM266 NVvQd|diT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHe0RlEyODBibl2= MVG3NkBp MXHJcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36gc4YhX01{Nk[gZ4VtdCCqYYLic5VzcW6pIFLSRWYhXjZyMVSgcZV1[W62YYTpc44> NUPEcG9sOjN|MUe0OFY>
M257 NVHDPJpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL0ToYyODBibl2= NIfQU3I4OiCq NHzjeFhFd2W|IH7veEBqdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[= M3rjU|I{OzF5NES2
LCP NUDONGlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jWNlExOCCwTR?= M{Cy[FczKGh? NGroVHhKdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gUGNRKGOnbHygbIFz[m:3cnnu[{BDWkGIIG[2NFBTKG23dHHueIF1cW:w MVSyN|MyPzR2Nh?=
WM266 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHoRmoyODBibl2= MU[3NkBp NYXTSHR{UW6qaXLpeEBGWktzLUKgdIhwe3Cqb4L5cIF1cW:wIHnuJHdOOjZ4IHPlcIwhcGG{Yn;1dolv\yCEUlHGJHY3ODCGIH31eIFvfGG2aX;u M3PhV|I{OzF5NES2

... Click to View More Cell Line Experimental Data

In vivo Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. [1]

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (57.74 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
8 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 519.56
Formula

C23H20F3N5O2S2

CAS No. 1195765-45-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01723202 Active, not recruiting Follicular Thyroid Cancer|Insular Thyroid Cancer|Papillary Thyroid Cancer|Recurrent Thyroid Cancer Manisha Shah|National Comprehensive Cancer Network|Ohio State University Comprehensive Cancer Center November 7, 2012 Phase 2
NCT02672358 Not yet recruiting Non-Small-Cell Lung Cancer Novartis Pharmaceuticals|Novartis October 2017 Phase 2
NCT02447939 Withdrawn Melanoma GlaxoSmithKline May 2017 Phase 1
NCT02967692 Not yet recruiting Melanoma Novartis Pharmaceuticals|Novartis February 2017 Phase 3
NCT02858921 Not yet recruiting Melanoma Melanoma Institute Australia|Merck Sharp & Dohme Corp.|Novartis February 2017 Phase 2
NCT03026517 Recruiting Melanoma Memorial Sloan Kettering Cancer Center|Massachusetts General Hospital|Weill Medical College of Cornell University January 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products

Tags: buy Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) supplier | purchase Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) cost | Dabrafenib (GSK2118436) manufacturer | order Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID